MedKoo product information:

  123-I-MIP-1095

123-I-MIP-1095 is an iodine 123-radiolabled small molecule that exhibits high affinity for prostate-specific membrane antigen (PSMA) with potential use in molecular imaging. 123-I-MIP-1095, a radiolabeled glutamate-urea-lysine analogue, selectively binds PSMA, which allows imaging of PSMA-expressing prostate cancer cells with gamma scintigraph. PSMA is a transmembrane glycoprotein highly expressed by malignant prostate epithelial cells and vascular endothelial cells of various solid tumors. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Current developer:    Molecular Insight Pharmaceuticals.

1. Frank Femia1, Kevin Maresca1, Shawn Hillier1, John Marquis1, Eduard Luss-Lusis1, Craig Zimmerman1, John Joyal1, Brian Abeysekera1, James Kronauge1 and John Babich1; [123I]-MIP-1095 for targeting prostate cancer via prostate specific membrane antigen (PSMA): A high specific activity radiosynthesis, J Nucl Med. 2008; 49 (Supplement 1):99P.